255 related articles for article (PubMed ID: 28833682)
21. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.
Zhang Y; Qian Q; Qian G; Sun G
Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196
[TBL] [Abstract][Full Text] [Related]
22. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Hakeam HA; Alkhani M; Alyahya Z; Alawaji Z; Ofori S
J Cardiovasc Pharmacol; 2021 Dec; 78(6):867-874. PubMed ID: 34882113
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein.
Margelidon-Cozzolino V; Hodin S; Jacqueroux E; Delézay O; Bertoletti L; Delavenne X
J Pharmacol Exp Ther; 2018 Jun; 365(3):519-525. PubMed ID: 29572341
[TBL] [Abstract][Full Text] [Related]
24. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
25. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.
Lessire S; Douxfils J; Pochet L; Dincq AS; Larock AS; Gourdin M; Dogné JM; Chatelain B; Mullier F
Clin Appl Thromb Hemost; 2018 Jan; 24(1):129-138. PubMed ID: 27811211
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
Freyburger G; Macouillard G; Khennoufa K; Labrouche S; Molimard M; Sztark F
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):925-33. PubMed ID: 26258673
[TBL] [Abstract][Full Text] [Related]
27. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
[TBL] [Abstract][Full Text] [Related]
28. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
29. Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.
Wright C; Brown R; Cuker A
Int J Lab Hematol; 2017 May; 39 Suppl 1():31-36. PubMed ID: 28447413
[TBL] [Abstract][Full Text] [Related]
30. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
31. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
32. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
[TBL] [Abstract][Full Text] [Related]
33. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants.
Sennesael AL; Exner T; Chatelain B; Lessire S; Larock AS; Vancraeynest C; Pochet L; Dogné JM; Spinewine A; Mullier F; Douxfils J
Thromb Res; 2017 Sep; 157():29-37. PubMed ID: 28686914
[TBL] [Abstract][Full Text] [Related]
34. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
[TBL] [Abstract][Full Text] [Related]
35. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
[TBL] [Abstract][Full Text] [Related]
36. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
37. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
Adelmann D; Wiegele M; Wohlgemuth RK; Koch S; Frantal S; Quehenberger P; Scharbert G; Kozek-Langenecker S; Schaden E
Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
[TBL] [Abstract][Full Text] [Related]
38. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
40. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
